NASDAQ:RLYB

Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

Retrieved on: 
Tuesday, May 10, 2022
Other Health, Research, General Health, Pharmaceutical, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Other Science, Health, Forward-looking statement, University, Mortality, U.S. Securities and Exchange Commission, Nasdaq, Lists of diseases, Biotechnology, Microdeletion syndrome, Corporation, Patient, Disease, Degenerative disease, Anemia, Erythropoiesis, Beta thalassemia, Hematology, MDS, CMC, SEC, Research, Iron overload, Pharmaceutical industry, Sanofi

With our strong focus on portfolio expansion, the in-licensing of RLYB331, our first as a public company, marks a pivotal moment for Rallybio.

Key Points: 
  • With our strong focus on portfolio expansion, the in-licensing of RLYB331, our first as a public company, marks a pivotal moment for Rallybio.
  • We believe RLYB331 is differentiated from all programs in clinical development based on its mechanism of action, with the potential to be first-in-class.
  • This product candidate is a natural fit with our R&D expertise and our focus on hematological disorders.
  • Rallybio plans to prosecute preclinical activities for RLYB331 including CMC, and dose-range finding and toxicity studies, which will then support transition of the asset into clinical development.

Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors

Retrieved on: 
Monday, April 4, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Therapy, Hematology, Degenerative disease, Actelion, SEC, Biotechnology, Research, The, Chief commercial officer, CEO, Goldman Sachs, Nasdaq, Master of Business Administration, University, Chairperson, Executive, Marketing, Peking University, Molecular biology, LLC, Industry, Business administration, Hope, U.S. Securities and Exchange Commission, Lists of diseases, Stanford University, Bachelor, Hypertensive emergency, Forward-looking statement, Growth, Board, Corporation, Board of directors, Public policy, CM, Patient, Horizon Therapeutics, Company, Business development, Citigroup, Principal, Doctor of Philosophy, MBA, Acquisition, Pharmaceutical industry, Management, Hyperion, Biology, Science, Pfizer, Meru University of Science and Technology, Director, MS. NASH, DR. LIU, RALLYBIO

notified the company that he will resign from the Board, effective at Rallybios 2022 annual meeting of shareholders.

Key Points: 
  • notified the company that he will resign from the Board, effective at Rallybios 2022 annual meeting of shareholders.
  • On behalf of our directors, I am pleased to welcome Christine and Hui to Rallybios Board.
  • He has been an outstanding friend, investor, board member and counselor and we have benefitted from Tims deep experience in guiding biotechnology companies.
  • Dr. Liu added, I am delighted to join Christine and Rallybios Board of Directors and collaborate with the Board and the Rallybio team to support their mission of bringing hope to patients suffering from rare diseases.

Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Tuesday, March 15, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, U.S. Securities and Exchange Commission, SEC, Pharmacokinetics, General Administration of Sport of China, University, Administration, Research and development, Patient, ENPP1, HPP, GMG, C5, Thrombosis, Nasdaq, Antibody, Forward-looking statement, G&A, Safety, Lists of diseases, IND, Quarter, PNH, Hypophosphatasia, Research, Degenerative disease, Hematology, Biotechnology, R, International Society, PK, Corporation, Pharmaceutical industry, Risk management

We look forward to a number of upcoming milestones in the year ahead, said Martin Mackay, Ph.D., Chief Executive Officer of Rallybio.

Key Points: 
  • We look forward to a number of upcoming milestones in the year ahead, said Martin Mackay, Ph.D., Chief Executive Officer of Rallybio.
  • We expect to initiate a subsequent Phase 1b proof-of-concept study in the second quarter and to announce initial data in the third quarter of 2022.
  • Fourth Quarter and Full Year 2021 Financial Results:
    Research & Development (R&D) Expenses: R&D expenses were $6.1 million for the fourth quarter of 2021, compared to $7.5 million for the same period in 2020.
  • General & Administrative (G&A) Expenses: G&A expenses were $6.2 million for the fourth quarter of 2021, compared to $2.6 million for the same period in 2020.

Rallybio to Present at the Cowen 42nd Annual Health Care Conference

Retrieved on: 
Monday, February 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Nasdaq, Conference, University, Patient, Lists of diseases, Corporation, Webcast, Hematology, Research, Degenerative disease, Pharmaceutical industry

A webcast of the panel discussion will be accessible through the Events and Presentations section of Rallybios website at www.rallybio.com .

Key Points: 
  • A webcast of the panel discussion will be accessible through the Events and Presentations section of Rallybios website at www.rallybio.com .
  • An archived replay of the webcast will be available for 30 days following the conference.
  • Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases.
  • Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticuts Technology Incubation Program in Farmington, Connecticut.